The FDA granted accelerated approval to selpercatinib (Retevmo) for the treatment of pediatric patients aged 2 years and older with RET-altered metastatic thyroid cancer or solid tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,